Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02

Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

Published:2024-06-29 Issue:1 Volume:21 Page:
ISSN:1743-422X
Container-title:Virology Journal
language:en
Short-container-title:Virol J

Author:

Wieczorek Lindsay,Chang David,Sanders-Buell Eric,Zemil Michelle,Martinez Elizabeth,Schoen Jesse,Chenine Agnes-Laurence,Molnar Sebastian,Barrows Brittani,Poltavee Kultida,Charurat Man E.,Abimiku Alash’le,Blattner William,Iroezindu Michael,Kokogho Afoke,Michael Nelson L.,Crowell Trevor A.,Ake Julie A.,Tovanabutra Sodsai,Polonis Victoria R.,Bartolanzo Danielle,Reynolds Alexus,Song Katherine,Milazzo Mark,Francisco Leilani,Mankiewicz Shauna,Schech Steven,Golway Alexandra,Omar Badryah,Mebrahtu Tsedal,Lee Elizabeth,Bohince Kimberly,Parikh Ajay,Hern Jaclyn,Duff Emma,Lombardi Kara,Imbach Michelle,Eller Leigh Anne,Kibuuka Hannah,Semwogerere Michael,Naluyima Prossy,Zziwa Godfrey,Tindikahwa Allan,Mutebe Hilda,Kafeero Cate,Baghendaghe Enos,Lwebuge William,Ssentogo Freddie,Birungi Hellen,Tegamanyi Josephine,Wangiri Paul,Nabanoba Christine,Namulondo Phiona,Tumusiime Richard,Musingye Ezra,Nanteza Christina,Wandege Joseph,Waiswa Michael,Najjuma Evelyn,Maggaga Olive,Kenoly Isaac Kato,Mukanza Barbara,Maswai Jonah,Langat Rither,Ngeno Aaron,Korir Lucy,Langat Raphael,Opiyo Francis,Kasembeli Alex,Ochieng Christopher,Towett Japhet,Kimetto Jane,Omondi Brighton,Leelgo Mary,Obonyo Michael,Rotich Linner,Tonui Enock,Chelangat Ella,Kapkiai Joan,Wangare Salome,Kesi Zeddy Bett,Ngeno Janet,Langat Edwin,Labosso Kennedy,Rotich Joshua,Cheruiyot Leonard,Changwony Enock,Bii Mike,Chumba Ezekiel,Ontango Susan,Gitonga Danson,Kiprotich Samuel,Ngtech Bornes,Engoke Grace,Metet Irene,Airo Alice,Kiptoo Ignatius,Owuoth John,Sing’oei Valentine,Rehema Winne,Otieno Solomon,Ogari Celine,Modi Elkanah,Adimo Oscar,Okwaro Charles,Lando Christine,Onyango Margaret,Aoko Iddah,Obambo Kennedy,Meyo Joseph,Suja George,Adamu Yakubu,Azuakola Nnamdi,Asuquo Mfreke,Tiamiyu Abdulwasiu Bolaji,Mohammed Samirah Sani,Okoye Ifeanyi,Odeyemi Sunday,Suleiman Aminu,Umejo Lawrence,Enas Onome,Mbachu Miriam,Chigbu-Ukaegbu Ijeoma,Adai Wilson,Odo Felicia Anayochukwu,Abdu Rabi,Akiga Rosemary,Nwandu Helen,Okolo CHisara,Okeke Ndubuisis,Parker Zahra,Linus Asogwa Ugochukwu,Agbaim Concilia Amaka,Adegbite Tunde,Harrison Nkenchiere,Adelakun Adewale,Chioma Ekeocha,Idi Victoria,Eluwa Rachel,Nwalozie Jumoke,Faith Igiri,Okanigbuan Blessing,Emmanuel Achugwo,Nnadi Nkiru,Rosemary Ndubuisi,Natalie Uzoegwu Amaka,Owanza Obende Theresa,Francis Falaju Idowu,Elemere Jacintal,Lauretta Obilor Ifeoma,Akinwale Edward,Ochai Inalegwu,Maganga Lucas,Bahemana Emmanuel,Khamadi Samoel,Njegite John,Lueer Connie,Kisinda Abisai,Mwamwaja Jaquiline,Mbwayu Faraja,David Gloria,Mwaipopo Mtasi,Gervas Reginald,Mkondoo Doroth,Somi Nancy,Kiliba Paschal,Mwaisanga Gwamaka,Msigwa Johnisius,Mfumbulwa Hawa,Edwin Peter,Olomi Willyhelmina,Charurat Manhattan,Abayomi Aka,Adebajo Sylvia,Baral Stefan,Gaydos Charlotte,Hu Fengming,Malia Jennifer,Nowak Rebecca,Ononaku Uchenna,Peel Sheila,Ramadhani Habib,Robb Merlin,Rodriguez-Hart Cristina,Shoyemi Elizabeth,Tiamiyu Abdulwasiu,Vasan Sandhya,

Abstract

AbstractThe magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg. to sCD4, MPER and V2/V3 monoclonal antibodies), as well as in properties such as variable loop lengths, number of potential N-linked glycans and charge, demonstrating distinct antigenic characteristics of CRF02_AG and subtype G. There was preferential neutralization of the matched CRF/subtype when PSV from subtype G or CRF02_AG were tested using pooled plasma. These novel Nigerian PSV will be useful to study HIV-1 CRF- or subtype-specific humoral immune responses for subtype G and CRF02_AG.

Funder

U.S. Department of Defense

National Institutes of Health

U.S. President’s Emergency Plan for AIDS Relief

Fogarty Epidemiology Research Training for Public Health Impact in Nigeria program

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12985-024-02394-y.pdf

Reference57 articles.

1. Onovo AA, Adeyemi A, Onime D, Kalnoky M, Kagniniwa B, Dessie M, et al. Estimation of HIV prevalence and burden in Nigeria: a Bayesian predictive modelling study. EClinicalMedicine. 2023;62:102098. https://doi.org/10.1016/j.eclinm.2023.102098. (Epub 2023/08/04. PubMed PMID: 37538543; PubMed Central PMCID: PMCPMC10393599).

2. National Summary Sheet - Prelimiary Findings. National HIV/AIDS Indicator and Impact Survey, 2019.

3. UNAIDS. UNAIDS Data 2022. 2022.

4. Keshinro B, Crowell TA, Nowak RG, Adebajo S, Peel S, Gaydos CA, et al. High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. J Int AIDS Soc. 2016;19(1):21270. https://doi.org/10.7448/ias.19.1.21270. (Epub 2016/12/10. PubMed PMID: 27931519; PubMed Central PMCID: PMCPMC5146323).

5. Crowell TA, Danboise B, Parikh A, Esber A, Dear N, Coakley P, et al. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries. Clin Infect Dis. 2021;73(7):e2311–22. https://doi.org/10.1093/cid/ciaa1161. (Epub 2020/08/14. PubMed PMID: 32785695; PubMed Central PMCID: PMCPMC8492117).